Kos Biotechnology Partners Announces Third Closing of Inaugural Global Life Sciences Fund
Kos Biotechnology Partners, a global life sciences investment firm, has announced the third closing of its inaugural global life sciences fund, reaching total capital commitments of $123M (€106M). The fund has garnered support from institutional investors and family offices, with the Hellenic Development Bank of Investments (HDBI) as the lead investor.
As the first life sciences-dedicated investment fund in Greece, Kos Biotechnology Partners has made history with the largest venture capital fund launch in the country and one of the largest first-time life sciences VC launches in Europe. The firm invests strategically across all stages of development, focusing on biotech/novel therapeutics, pharma services, and tech-enabled technologies.
Dr. Simos Simeonidis, Co-Founder and Managing Partner of Kos, highlights the potential of combining novel biology with data science and advanced computing to address complex diseases. The firm aims to support exceptional entrepreneurs in redefining the standard of care by leveraging its international network to connect US drug development expertise with scientific talent.
Founded by Dr. Simos Simeonidis and Alex Tzoukas, Kos Biotechnology Partners brings together Wall Street institutional investing experience and scientific domain knowledge to advance the life sciences ecosystem in Greece. The firm's successful fundraising demonstrates the potential of bridging US scientific innovation with Europe's growing life sciences sector, offering flexible investment options across all growth stages to support innovators in improving human health.
In conclusion, Kos Biotechnology Partners' latest fund closing marks a significant milestone in the firm's mission to drive innovation in the life sciences industry by connecting global expertise and resources to support groundbreaking advancements in healthcare.